Phio Pharmaceuticals’ PH-762 Skin Cancer Study Charges to Fourth Dose

April 9, 2025

DENVER, Colo., Apr 09, 2025 (247marketnews.com)- Phio Pharmaceuticals (NASDAQ:PHIO) reports positive data from its INTASYL PH-762 skin cancer trial. Announced today, the Safety Monitoring Committee (SMC) gave a green light to crank PH-762’s Phase 1b trial (NCT 06014086) to its fourth dose cohort, signaling this siRNA champ’s safety profile is rock-solid—and tariffs? Down here, they’re just background noise.

Mary Spellman, MD, Phio’s acting Chief Medical Officer, said, “We are impressed with the continuing safety profile of PH-762 having now progressed through the first 3 escalating doses.”

PH-762, Phio’s lead weapon against cutaneous cancers, aced its third cohort—three patients with squamous cell carcinoma took the intratumoral shots, with no serious adverse events or dose-limiting toxicities. Pathology results are pending, but earlier cohorts dazzle: in cohort two (four patients), two nailed a complete response (100% tumor clearance) by Day 36, one hit a 90% partial response, and the fourth held steady. Cohort one’s three patients all stayed stable too—no tariff woes here, just U.S.-driven biotech grit slashing cancer in an estimated $10 billion skin cancer market.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PHIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.